XTL Biopharma Files 6-K Announcing Share Purchase Agreement
Ticker: XTLB · Form: 6-K · Filed: Apr 29, 2026 · CIK: 0001023549
| Field | Detail |
|---|---|
| Company | Xtl Biopharmaceuticals Ltd (XTLB) |
| Form Type | 6-K |
| Filed Date | Apr 29, 2026 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: share-purchase-agreement, corporate-action, filing
TL;DR
XTL Biopharma just filed a 6-K for a Share Purchase Agreement - big news incoming!
AI Summary
XTL Biopharmaceuticals Ltd. filed a Form 6-K on April 29, 2026, reporting a Share Purchase Agreement. The filing includes a press release detailing this agreement, which is a significant event for the company. The specific terms and parties involved in the Share Purchase Agreement are not detailed in this summary but are available in the attached documents.
Why It Matters
This filing indicates a significant corporate action, likely a merger, acquisition, or divestiture, which could impact the company's future operations and stock value.
Risk Assessment
Risk Level: medium — Share purchase agreements can involve substantial financial commitments and strategic shifts, carrying inherent risks.
Key Numbers
- 25258 — 6-K Document Size (Size of the primary 6-K filing document.)
- 219582 — EX-99.1 Document Size (Size of the Share Purchase Agreement exhibit.)
- 23801 — EX-99.2 Document Size (Size of the Press Release exhibit.)
Key Players & Entities
- XTL Biopharmaceuticals Ltd. (company) — Filer of the 6-K and party to the Share Purchase Agreement
- April 29, 2026 (date) — Filing date and period of report
- 0001023549 (company) — CIK number for XTL Biopharmaceuticals Ltd.
FAQ
What is the nature of the Share Purchase Agreement filed by XTL Biopharmaceuticals Ltd.?
The filing includes the Form of Share Purchase Agreement (EX-99.1) and a related Press Release (EX-99.2) dated April 29, 2026, indicating a significant transaction.
When was this Form 6-K filed with the SEC?
The Form 6-K was filed on April 29, 2026.
What are the key documents included in this 6-K filing?
The filing includes the main 6-K report, the Form of Share Purchase Agreement (EX-99.1), and a Press Release (EX-99.2).
What is the CIK number for XTL Biopharmaceuticals Ltd.?
The CIK number for XTL Biopharmaceuticals Ltd. is 0001023549.
What is the SIC code associated with XTL Biopharmaceuticals Ltd.?
The SIC code is 2834, which corresponds to Pharmaceutical Preparations.
Filing Details
This Form 6-K (Form 6-K) was filed with the SEC on April 29, 2026 regarding XTL BIOPHARMACEUTICALS LTD (XTLB).